WuXi Biologics (Cayman) valuation

2269 · HKEX · HKD

Compare WuXi Biologics (Cayman)
$46.30Change from previous close: −0.94%Absolute change: −$0.44

Close · November 17, 2026

Valuation

The P/E ratio is 35.1. The average price target of 23 analysts is $60.30.

Data as of November 17, 2026

WuXi Biologics (Cayman) compared with similar companies

WuXi Biologics (Cayman)'s P/E (trailing 12 months): 35.1, −12% against the median of a group of 8 similar companies (40.0).

WuXi Biologics (Cayman)'s metrics compared with similar companies
MetricWuXi Biologics (Cayman)Median25th–75th percentileBand
P/E (trailing 12 months)35.140.034.2 – 60.9Middle
Forward P/E21.430.724.3 – 37.8Low
EV/EBITDA20.825.321.2 – 42.0Low
Price/book3.406.043.96 – 9.42Low
Price/sales8.1410.07.09 – 17.7Middle
Gross margin47.5%73.6%52.7% – 76.9%Low
Operating margin32.4%26.8%10.7% – 32.0%High
Net margin21.2%11.1%7.2% – 26.8%Middle
ROE11.4%10.4%5.0% – 16.3%Middle
Debt/equity0.050.210.08 – 0.40Low

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
$192.4B
Enterprise value
$188.07B
PEG
0.62
EV/revenue
7.96

Profitability and growth

ROA
7.6%
ROIC
13.9%
Revenue growth (year over year)
18.4%
Earnings growth (year over year)
4.3%

Financial health

Total cash
$13.03B
Total debt
$2.73B
Current ratio
3.32
Quick ratio
2.64
Altman Z-Score
8.62
Piotroski F-Score
7.00

Dividends

Dividend yield
0.0%
Payout ratio
0.0%

Analysts and estimates

Average price target
$60.30
Median price target
$60.57
High price target
$79.73
Low price target
$39.44
Analysts with a price target
23
Consensus
Strong buy
Forward EPS
$2.18
EPS estimate, current year
$1.55

Shares and trading

Beta
0.59
Average volume
35.43M
Shares outstanding
4.12B
Float
3.8B
Institutional ownership
37.0%
Insider ownership
7.9%